VIB is proud to share that our spin-off, Augustine Therapeutics, has successfully completed a major Series A financing round. 🎉 👉 Read more: https://lnkd.in/e2EPUYut This key milestone supports the company’s mission to develop next-generation therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases through its innovative and highly selective HDAC6 inhibition approach. 👏 Congratulations to the entire team at Augustine Therapeutics – we’re excited to follow your continued progress on this impactful journey! #Biotech #Innovation #SeriesA #CharcotMarieTooth #CMTAFamily #CMTRF
Congratulations
Drug Discovery Consultant; Research Fellow Department of Molecular Design & Synthesis
3wCongrats, well done